Novartis acquires US pharma research firm Selexys Pharmaceuticals

AFP

© AFP | Novartis, a major Swiss pharmaceutical company, is to buy research lab Selexys Pharmaceuticals Corp., which specialises in sickle cell disease, an inherited form of anaemia most common among people of African descent

ZURICH (AFP) – Swiss-based pharmaceuticals giant Novartis said Monday it was acquiring Selexys Pharmaceuticals Corp., a US research lab in blood and inflammatory disorders, in a deal costing up to $665 million (627 million euros).

Selexys specialises in sickle cell disease, an inherited form of anaemia that is most common among people of African descent.

In a statement, Novartis said it exercised rights to buy the company after seeing results from a large trial into a drug to treat pain for people with the disease.

The drug, called SelG1, aims at easing so-called vaso-occlusive pain crises, which happen when sickle-shaped red blood cells block the flow through blood vessels.

The prototype treatment has just completed the second phase of the three-phase process to test new drugs for safety and effectiveness.

“Sickle cell disease affects millions of people around the world and there are limited therapies available for treatment of vaso-occlusive pain crises, a very common complication of the disease,” Bruno Strigini, head of CEO of Novartis Oncology, said in the statement.

Tags: , , , , , , , , , , , ,

One Response to “Novartis acquires US pharma research firm Selexys Pharmaceuticals”

  1. daveyone1 Says:

    Reblogged this on World Peace Forum.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: